Journal of King Saud University - Science 35 (2023) 102514

Contents lists available at ScienceDirect

Journal of King Saud University – Science

journal homepage: www.sciencedirect.com

Original article

HOSTED BY

Modelling the Anticancer Activity of 4-Alkoxy Cinnamic Analogues using 3D-Descriptors and Genetic Algorithm-Multiple Linear Regression (GA-MLR) Method



Herlina Rasyid, Nunuk Hariani Soekamto, Seniwati, Syadza Firdausiah, Firdaus*

Department of Chemistry, Faculty of Mathematics and Natural Science, Hasanuddin University, South Sulawesi, Indonesia

ARTICLE INFO

Article history: Received 30 June 2021 Revised 12 December 2022 Accepted 15 December 2022 Available online 22 December 2022

Keywords: QSAR modelling 3D Descriptors 4-alkoxy cinnamic

ABSTRACT

QSAR modelling as anticancer of 4-alkoxy cinnamic analogues has been done against their 3D descriptors. This modelling aims to develop the 4-alkoxy cinnamic analogues in better activity. We employed Kennard and Stone's algorithm to split the data set into training and test set. Genetic Algorithm (GA) and Multiple Linear Regression (MLR) are used to select the influencing descriptors and to carry out statistically robust model.

 plC_{50} = 2.7350 (±1.0653) $\times RDF145u$ - 2.2276 (±0.9655) \times RDF120m + 1.8369 (±1.1295) \times E2m - 1.5611 (±0.4518)

 $(R_{\text{training}}^2 = 0.7436, R_{\text{test}}^2 = 0.9812)$

Coefficient of Y-randomization (cR_p^2) as one of model validation for the selected model gave a value of 0.6569 that greater than 0.5 identifying the model is powerful and not inferred by chance. Descriptors which influencing the activity are RDF145u, RDF120m, and E2m. RDF145u is radial distribution function-145/unweighted, RDF120m is radial distribution function-120/weighted by atomic mass and E2m is 2nd component accessibility directional WHIM index, weighted by atomic mass. Selected QSAR model used to design and predict some of new 4-alkoxy cinnamic analogues. There are 10 newly designed compounds that have a better prediction activity and have no violation in the drug likeness property based on the Lipinski rule.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cinnamic acid is one of chemical substances found in plants or fruit. Its derivatives have been identified as interesting compounds with multifunctional activities (Peperidou et al., 2017) such as

Production and hosting by Elsevier

* Corresponding author.

E-mail address: firdaus@unhas.ac.id (Firdaus).

Peer review under responsibility of King Saud University.

ELSEVIER

inhibitor α -glucosidase (Adisakwattana et al., 2009), antimicrobial (Narasimhan et al., 2004), antifungal (Bisogno, 2007), antioxidant (Sova, 2012), and anticancer (J. A. do Vale, , 2022). As an anticancer, cinnamic acid derivatives are effectives to inhibit the growth of cancer in various type of cancers. One of their derivatives, cinnamaldyhde, inhibit and destroy the cancer cell through apoptosis mechanism. The other potential derivative of cinnamic acid is 4-alkoxy cinnamic group.

4-alkoxy cinnamic groups are a derivative of cinnamic acid that have been studied as anticancer through P388 leukemia cell line, which began when *p*-coumaramide successfully isolated from *Kleinhovia Hospita* L. and has IC_{50} value of 44 µg/mL (Firdaus, 2009). Modifications through the structure of 4-alkoxy cinnamic groups show the increasing and decreasing activity based on the type of functional group as the substituents. Despite as anticancer, this analogues were also reported as inhibitors of M. Tuberculosis (Adeniji et al., 2020) and α -glucosidase inhibitor (Ernawati et al., 2020). However, development of anticancer agent was in line with the increasing of inhibitor's toxicity such cardiovascular toxicity

https://doi.org/10.1016/j.jksus.2022.102514

1018-3647/© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: GA, Genetic Algorithm; MLR, Multiple Linear Regression; CR²_p, Coefficient of Y-randomization; RDF145u, Radial Distribution Function-145/ unweighted; RDF120m, Radial Distribution Function-120/weighted by atomic mass; E2m, 2nd component accessibility directional WHIM index, weighted by atomic mass; DFT, Density Functional Theory; DTC, Drug Theoretics and Cheminformatics; R², Coefficient of determination; Q², Cross validated; h*, Leverage critical value.

that found as a side effect when threating by small molecule tyrosine kinase inhibitor. Perceived side effect can be hypertension, congestive heart failure, heart disease, etc (Brown et al., 2016). This side effect making a researcher should develop and found the new cancer inhibitors. One way to find a new potential drug molecule is by using computational drug design such as Quantitative Structure Activity Relationship (QSAR). This tool could understand the relationship between the structure compound and their activity (Iman et al., 2014).

OSAR analysis has been a common tool in novel drug design based on ligand approach. This computational tool helps the researchers to minimize the cost and time-consuming during synthesis stage. Qsar analysis of 4-alkoxy cinnamic derivatives has been performed as M. Tuberculosis inhibitors (Adeniji et al., 2020). However, QSAR study of 4-alkoxy cinnamic analogues as anticancer through P388 cell line has never been modelled. This research focused on the finding of the new 4-alokxy cinnamic derivatives as anticancer through QSAR analysis by using 24 compounds that we had synthesized since 2019 until now. In this 3D-QSAR analysis, Genetic Algorithm (GA) (Labjar et al., 2022) parallelized with Multi Linear Regression (MLR) were attempted (Jawarkar, 2022). GA is chosen to develop the QSAR equation since this algorithm has an effective and easy procedure to attempt in QSAR modelling (Serra et al., 2020). This algorithm is combined with MLR due to the transparency, effectiveness and the easy step to conduct this method in a good accuracy (Arthur et al., 2016). This study aims to develop the relationship between 4-alkoxy cinnamic structure and their activity to the P388 cell line, then predict a newly potent analogues to be synthesized in our next research.

2. Materials and method

2.1. Data collection

Twenty-three molecules of 4-alkoxy cinnamic analogues used in this research as potent anticancer through P388 cell line. All molecules were collected from some of our reported articles since 2012 until 2021 (Firdaus, 2009; Firdaus et al., 2017, Firdaus et al., 2018, Firdaus et al., 2019, Firdaus et al., 2020a, Firdaus et al., 2020b, Firdaus et al., 2021a, Firdaus et al., 2021b, Firdaus et al., 2021c). Bioactivity of all analogues was determined as inhibition concentration 50 % (IC₅₀) then converted as logarithmic scale (pIC₅₀) in order to obtain normal distribution. The structures and bioactivity values of analogues are shown in Table 1.

2.2. QSAR equation development

All analogues were drawn by using Avogadro software (Hanwell et al., 2012) as 3D structures then optimized using ORCA software by employing DFT B3LYP/6-31G(d,p) method. The reason for choosing DFT is due to this method could give a better performance than semiempirical method but still lower computational time than Ab Initio method (Schwöbel et al., 2011). After choosing DFT as the main method, then we were varying the density functional method and validated using ¹H NMR data from one of derivative compounds. The result showed that DFT B3LYP/6-31G (d,p) showed the highest coefficient determinant value (R²) than the other density functional method such as LSDA, BPV86, and B3PW91.

Output file from optimization stage was then converted as.mol file type by using Open Babel software (O'Boyle et al., 2011). In this research, we employed PaDEL-Descriptor (Yap, 2011) software to obtain 3D-Descriptor of all analogues, which resulted 431 descriptors. Before dividing data into training and test set, we did normalization and data pretreatment. Data normalization aims to ensure

that all descriptors data have the same opportunity in building a good qsar model (Adeniji et al., 2020). Data pretreatment used to remove the redundant data. The result of data pretreatment reduces the number of descriptors from 431 to only 306 descriptors. The software used for normalization and data pretreatment retrieved from Drug Theoretics and Cheminformatics (DTC) laboratory (dtclab.webs.com). After reducing the total descriptors, all data was divided into training and test set employing Data Division software also from DTC Lab by treating Kennard and Stone's algorithm (Kennard and Stone, Feb. 1969). Training set data include 80 % of data and remaining data categorized as test set data for external validation purposes. QSAR models were developed by using BuildQSAR software (De Oliveira and Gaudio, 2000) applying Genetic Algorithm (GA) to select the influencing variable and Multi Linear Regression (MLR) to establish the gar equation. Only three variables were selected due to the number of training set data which about 18 compounds. Each of gsar equations were evaluated through internal and external validations.

2.3. Internal and external validations

There are 4 qsar models resulted by variable selections in BuildQSAR. Each models were assessed using some of statistical parameters. Coefficient of determination (R^2) is defined as:

$$R^{2} = \left[\frac{N\sum XY - (\sum X)(\sum Y)}{\sqrt{\left(\left[N\sum X^{2} - (\sum X)^{2}\right]\left[N\sum Y^{2} - (\sum Y)^{2}\right]\right)}}\right]$$

where a good qsar model indicated if coefficient of determination equal to or more than 0.6, beside observed the R^2 value, the difference between R^2 and R^2_{Adj} was also calculated. If the difference is less than 0.3,the acceptability of total descriptors involved in the model.

Cross validated (Q^2) is another statistical parameter used in this validation stage. Q^2 is defined as:

$$Q^{2} = \frac{\sum_{i=1}^{N} (y_{pred,i} - y_{i})^{2}}{\sum_{i=1}^{N} (y_{i} - y_{m})^{2}}$$

Standard of Q^2 value is more than 0.5 and the difference of $R^2 - Q^2$ value should not more than 0.3 to give a good predictability.

Y-Randomization test is one of internal validation utilized in this stage. In this validation, a randomized R^2 and Q^2 which have a lower value than R^2 and Q^2 indicated that the qsar model is reliable (Tropsha et al., 2003). Coefficient of determination (cR_p^2) in Y-randomization value should be greater or near 0.5 which indicate that the model is acceptable.

External validation that used at this stage is coefficient of determination (R_{test}^2) value. A better qsar model has a coefficient of determination closed to 1. Additional statistical validation applied was the evaluation of the applicability domain of the selected qsar model. The leverage approach wasadopted in applicability domain. A good qsar model shown is if the leverage value lower than its critical value (h*), which defined as:

$$h^* = 3\frac{(k+1)}{n}$$

where k is the number of descriptors and n is the sum of training set compound (Teraishi, Aug. 2005).

2.4. Designing new analogues and evaluation of druglikeness property

New analogues were designed by changing the substituents (R1, R2, and R3) of the core structure. The selected qsar model rep-

Table 1

Structure and bioactivity of 4-alkoxy cinnamic analogues as anticancer



N -		· ·2	P		
NO.	K ₁	R ₂	<i>K</i> ₃	IC ₅₀	pIC ₅₀
1	-OCH ₃	-OH	-H	16.15	-1.21
2	-OCH ₃	-OCH ₃	-Н	21.18	-1.33
3	-NH ₂	-OH	-Н	44.00	-1.64
4	<i>N</i> -diethyl	-OH	-Н	23.50	-1.37
5	N-propyl	-OH	-Н	53.56	-1.73
6	<i>N</i> -butyl	-OH	-OH	0.609	0.22
7	N-benzyl	-OH	-Н	16.15	-1.21
8	N-benzyl	-OH	-OH	674.38	-2.83
9	<i>N</i> -benzyl	-OH	-OCH ₃	179.56	-2.25
10	piperidinil	-OH	-H	5.34	-0.73
11	piperidinil	-OH	-OCH ₃	46.67	-1.67
12	piperidinil	-OH	-OH	0.861	0.06
13	pyrolidinil	-OH	-Н	53.46	-1.73
14	pyrolidinil	-OH	-OH	11.35	-1.05
15	morpholine	-OH	-Н	19.35	-1.29
16	morpholine	-OH	-OH	1.48	-0.17
17	0	-ОН	–OCH ₃	10.79	-1.03
18	0	-ОН	-H	1.0	0.00
19	HN	-OH	–OCH ₃	29.14	-1.46
20	HN	-OAc	-OAc	0.5	0.30
21	HN	-ОН	-H	5.89	-0.77
22	HN	-0H	-0H	0.91	0.04
23	HN CH ₃	-ОН	-H	16.97	-1.23

resent three influencing descriptors, which are RDF145u, RDF120m and E2m. The better bioactivity of new analogues is resulted if it has a lower value of RDF120m than RDF145u and higher E2m. After getting the nest newly design compound, we evaluated the druglikeness property by using the Lipinksi rule of five in Swissadme web server (Daina et al., 2017). If the compound had a good predicted bioactivity, it should had no violation in the Lipinski rule (Yalcin, 2020).

3. Result and discussion

This study focused on development of QSAR model between 4alokoxy cinnamic analogues and their bioactivity as anticancer in P388 cell lines. Kennard-Stone's algorithm was chosen to divide the 3D descriptor data into training and test set data. To make sure that the resulted division data had a good quality, univariate analysis was attempted. Table 2 present the result of univariate analysis data and it shows that test set value (-1.6400 to 0.2200) was in line with training set value (-2.8300 to 0.3000). Standard deviation of training data is close to test data value. Thereby, Kennard-

Table 2

Univariate analysis of the inhibition data.

Statistical parameters	Activity	Activity		
	Training set	Test set		
Mean	-1.1256	-0.7640		
Median	-1.2200	-1.0300		
Standard deviation	0.8189	0.8303		
Sample variance	0.6706	0.6893		
Kurtosis	-0.0276	-2.7205		
Skewness	0.0117	0.3532		
Minimum	-2.8300	-1.6400		
Maximum	0.3000	0.2200		
Number of sample points	18	5		

Table 3					
Validation	parameters	result	of each	qsar	model.

No.	Parameters	Model 1	Model 2	Model 3	Model 4
1	R ² training set	0.7436	0.7393	0.7584	0.7531
2	Adjusted R ²	0.6887	0.6835	0.7066	0.7002
3	$R^2 - R^2_{Adi}$	0.0549	0.0558	0.0518	0.0529
4	р	0.0002	0.0002	0.0001	0.0002
5	Q^2	0.6195	0.6341	0.6443	0.6006
6	N _{ext.test} set	5	5	5	5
7	r _m ² (overall)	0.6829	0.5551	0.4957	0.5815
8	R ² _{test set}	0.9812	0.8639	0.7543	0.6293

Stone's algorithm applied has produced the test set data that reflects training set data.

BuildQSAR software was used to obtain some of qsar models by using training set data. There were 4 qsar models produced and validated by some statistical parameters. Table 3 shows validation parameter resulted in each qsar models that generated from Genetic Algortihm (GA). All qsar models are eligible for the parameter of coefficient determination, but the selected qsar model is model 1 because it has the best value for some statistical parameters specifically in coefficient determination of test set data which about 0.9812, indicating the linear relationship in predicting bioactivity value.

The selected qsar model (Model 1) was conducted to calculate residual of the inhibition data between experimental and predicted data. Table 4 present the residual value of inhibition data, range of the difference value of experiment and predicted data is only about -0.89 until 0.69. This low residual value indicate that Model 1 is a good choice in predicted the inhibition value.

The standardized residual was also evaluated through the experimental value that is shown in Fig. 1. General rule to figure out the standardized value is that it should has the value close to zero. If the residual is less than -2, the observed data is less than the predicted data (Jalali-Heravi and Kyani, 2004). In our result, there is only one point that close to -2. However, the other values show the range between 0 and \pm 1, and the spread of values is close to 0.

Despite of internal and external validation explained before, Yrandomization test was performed to check the accuracy of Model 1 in prediction of inhibition activity. Table 5 shows the result of Yrandomization test for Model 1. Ten random models were resulted and then compared its R, R^2 , and Q^2 value to the original model (Model 1). The selected qsar model would be conclude as inaccurate if there is a strong correlation from the random R² value (R² > 0.5). Result of Y-randomization test shows that all of random models have a weak correlation to the bioactivities, thus the Model 1 could be inferred to have a responsive in predicted the bioactivities. Applicability domain is the last validation applied to Model 1. The critical value (h^{*}) of this model is 0.67 and the cut off is \pm 3. The William plot in Fig. 2 presents that there is no outlier in the training and test set data indicating the validity of the model. The QSAR equation of Model 1 resulted from Genetic Algorithm (GA) is.

pIC50 = 2.7350 (±1.0653) ×RDF145u - 2.2276 (±0.9655)× RDF120m + 1.8369 (±1.1295)× E2m - 1.5611 (±0.4518).

where there are three descriptors involved in the equation, namely RDF145u, RDF120m, and E2m. RDF descriptor is one of geometrical descriptor that describe the molecular structure in space. The alphabet **u** in RDF145u means unweighted method, while the notation 145 related to the distance between two atoms by distance about 14.5 Å. RDF120m belongs to the radii which about 12 Å from the center atom and alphabet **m** means the relative mass used as weighted method (Arief et al., 2021). E2m is referred to one of Weighted Holistic Invariant Molecular (WHIM) descriptor, positive sign for this descriptor means a comprehensive distribution of the mass and polarizability to the second principal axis and it influences the anticancer activity by the high pIC₅₀ (or lower IC₅₀ value).

Comparison of the resulted qsar model presents in Table 6. Based on our literature study, qsar analysis that use 4-alkoxy cinnamic acid derivative as anticancer has never been conducted. Arthur et al. (2016) build a qsar model in the same bioactivity as anticancer in P388 cell line but different dataset (Arthur et al., 2016). The other qsar study used cinnamic acid derivatives but have a different bioactivity such as anti-mycobacterium

able 4	Га	bl	e	4	
--------	----	----	---	---	--

Desideral	of inhibition	data antinity	hatriaam	arreading and a			
Residual	OI IIIIIIDIIIOII		nerween	experiment a	11(1 1	predicted val	ne
	01 11110101011	auca accivicy		criperniene a		sieureceu iui	

No.	Activity (pIC ₅₀)		Residual	Residual No.	Activity (pIC ₅₀)		Residual
	Experiment	Predicted		Experiment	Predicted		
1 ^a	-1.64	-1.56	-0.08	13 ^b	-2.25	-2.46	0.21
2 ^b	-1.73	-1.51	-0.22	14 ^a	-1.03	-1.21	0.18
3 ^a	-1.21	-1.16	-0.05	15 ^b	-1.46	-1.55	0.09
4 ^b	-0.73	-0.87	0.14	16 ^b	0.04	-0.59	0.63
5 ^b	-1.21	-1.53	0.32	17 ^b	-1.23	-0.82	-0.41
6 ^b	-1.33	-1.50	0.17	18 ^a	0.22	-0.47	0.69
7 ^b	-1.29	-0.85	-0.44	19 ^b	0.06	-0.55	0.61
8 ^b	-0.17	-0.79	0.62	20 ^b	0.30	0.38	-0.08
9 ^b	-1.73	-0.84	-0.89	21 ^a	0.00	-0.56	0.56
10 ^b	-1.05	-0.76	-0.29	22 ^b	-0.77	-0.87	0.10
11 ^b	-1.21	-1.26	0.05	23 ^b	-1.67	-1.17	-0.50
12 ^b	-2.83	-2.72	-0.11				

^a test set.

^b training set.



Fig. 1. Graphical plot of standardized residual and experimental activity.

Table 5Y-randomization test for Model 1.

Model	R	R ²	Q ²
Original	0.8620	0.7436	0.6190
Random 1	0.5160	0.2665	-0.5703
Random 2	0.3010	0.0905	-0.1961
Random 3	0.3150	0.0993	-0.7298
Random 4	0.2270	0.0513	-0.4004
Random 5	0.2020	0.0407	-0.4529
Random 6	0.5970	0.3569	-0.2629
Random 7	0.6780	0.4599	-0.0938
Random 8	0.2230	0.0497	-0.5161
Random 9	0.4990	0.2490	-1.1992
Random 10	0.4770	0.2276	-1.5962
Random models p	arameters		
average R	0.4035		
average R ²	0.2395		
average Q ²	-0.4908		
cR ² p	0.6569		

tuberculosis and acetylcholinesterase inhibitor. This comparison shows the novelty of this research and the great impact for the development anticancer agent in the future. To improve the anticancer activity of 4-alkoxy cinnamic analogues, we have to find functional groups that can improve the number of RDF145u and E2m but lower RDF120m. The list of new designed compounds is presented in Table 7 and it shows that compound **Q8** is the most active predicted compound which is derived from -NO2 substituent in R_3 position. Even after we changed the amine in R_1 position, it still shows that derivation of -NO₂ substituent still give a better predicted activity. This result was in line by the previous research that showed a potential of -NO₂ moiety in cinnamic acid derivatives could increase the bioactivity of the compounds (Ernawati et al., 2020). Evaluation of drug likeness property in Table 7 supports the ability of the newly design compounds to be use as a drug molecule due to the absence of violation in the Lipinski rule. Retrosynthetic analysis which is shown in Fig. 3 explain that compound Q8 is possible to synthesize by using *p*-methoxy



Fig. 2. The William Plot of the standardized residuals vs the leverage value.

Table 6

Comparison of the obtained result with some QSAR study.

No.	Bioactivity	Kind of descriptors	$R_{\rm train}^2$	R ² _{test}	Reference
1 2 3 4 5	Anticancer on P388 cell line Anticancer on P388 cell line Anti-mycobacterium tuberculosis Acetylcholinesterase inhibitor Anti-tubercular agents	3D 1D, 2D, 3D 1D, 2D, 3D 2D 1D, 2D, 3D	0.7436 0.9040 0.9809 0.79762 0.9429	0.9812 0.6700 0.8756 0.83852 0.8612	Present study (Arthur et al., 2016) (Adeniji et al., 2020) (Thakur et al., 2022) (Adeniji et al., 2018)
6	Acetylcholinesterase inhibitor	Molecular Descriptor	0.913	0.856	(Nekoeinia and Yousefinejad, 2021)

Table 7

List of newly designed compounds obtained from QSAR analysis and evaluation of drug likeness property





Fig. 3. Retrosynthesis analysis of compound Q8.

cinnamic acid as the starting material. The synthesis pathway consists of three steps of reaction, namely chlorination, amidation (Castral, 2011) and nitration (Giles, 2004). However, further research still requires to make sure that these design compounds are safe in patient such as *in vitro* and *in vivo* test.

4. Conclusion

A QSAR model between 3D descriptors and pIC50 data of 4alkoxy cinnamic analogues has been developed using Genetic Algorithm (GA) and employing Multi Linear Regression (MLR) method. The contributed descriptors are RDF145u, RDF120m, and E2m. The model has satisfied some of statistical parameters in the internal and external validation. The selected model (Model 1) is applied to design new analogues and resulted that compound **Q8** as the most active compound with IC₅₀ prediction value about 0.0019 $(\mu g/mL)$ and has no violation in the drug likeness property based on the Lipinski rule. This result contributes on the drug design field specially on the finding the new potential anticancer compound. The newly design compounds can be synthesized and tested through *in vivo* and *in vitro*.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank LPPM (Lembaga Penelitian dan Pengabdian Masyarakat) of Hasanuddin University for the research grant in

the scheme of Basic Research in 2021. The authors also thank to DTC (Drug Drug Theoretics and Cheminformatics) Laboratory for the web software used in this research.

References

- Adeniji, S.E., Uba, S., Uzairu, A., 2018. Theoretical modeling and molecular docking simulation for investigating and evaluating some active compounds as potent anti-tubercular agents against MTB CYP121 receptor. Futur. J. Pharm. Sci. 4 (2), 284–295. https://doi.org/10.1016/j.fjps.2018.10.003.
- Adeniji, S.E., Uba, S., Uzairu, A., 2020. Quantitative structure-activity relationship and molecular docking of 4-Alkoxy-Cinnamic analogues as anti-mycobacterium tuberculosis. J. King Saud Univ. - Sci. 32 (1), 67–74. https://doi.org/10.1016/j. jksus.2018.02.005.
- Adisakwattana, S., Chantarasinlapin, P., Thammarat, H., Yibchok-anun, S., 2009. A series of cinnamic acid derivatives and their inhibitory activity on intestinal αglucosidase. J. Enzyme Inhib. Med. Chem. 24 (5), 1194–1200. https://doi.org/ 10.1080/14756360902779326.
- Arief, I., Pranowo, H.D., Mudasir, M., Wijaya, K., 2021. In Silico Prediction of Betulinic Acid Derivatives' Cytotoxicity: Relationship between Topological Descriptors and CC₅₀ Value. Key Eng. Mater. 884, 282–289. https://doi.org/10.4028/ www.scientific.net/kem.884.282.
- Arthur, D.E., Uzairu, A., Mamza, P., Abechi, S., 2016. Quantitative structure-activity relationship study on potent anticancer compounds against MOLT-4 and P388 leukemia cell lines. J. Adv. Res. 7 (5), 823–837. https://doi.org/10.1016/ j.jare.2016.03.010.
- Bisogno, F.A.B. et al., 2007. Structure Antifungal activity relationship of cinnamic acid derivatives. J. Agric. Food Chem. 55, 10635–10640.
- Brown, S.-A., Nhola, L., Herrmann, J., 2016. Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an oppurtunity for systems-based approaches. Clin. Pharmacol. Ther. 101 (1), 65–80.
- Castral, T.C. et al., 2011. Synthesis of a combinatorial library of amides and its evaluation against the fall armyworm, Spodoptera frugiperda. J. Agric. Food Chem. 59 (9), 4822–4827. https://doi.org/10.1021/jf104903t.
- Daina, A., Michielin, O., Zoete, V., 2017. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7 (January), 1–13. https://doi.org/10.1038/srep42717.
- De Oliveira, D.B., Gaudio, A.C., 2000. BuildQSAR: a new computer program for QSAR analysis. Quant. Struct.-Act. Relat. 19, 599–601. https://doi.org/10.1002/1521-3838(200012)19:6<599::AID-QSAR599>3.0.CO;2-B.
- do Vale, J.A. et al., 2022. Synthesis of cinnamic acid ester derivatives with antiproliferative and antimetastatic activities on murine melanoma cells. Biomed. Pharmacother. 148. https://doi.org/10.1016/j.biopha.2022.112689.
- Ernawati, T., Mun'Im, A., Hanafi, M., Yanuar, A., 2020. Synthesis of cinnamamide derivatives and their α-glucosidase inhibitory activities. Sains Malaysiana 49 (2), 315–322. https://doi.org/10.17576/jsm-2020-4902-09.
- Firdaus, S., Alamsyah, N., Paramita, S., 2019. Synthesis and activity of N-(o-tolyl)caffeamide and N-(o-tolyl)-p-coumaramide against P388 leukemia murine cells. J. Phys. Conf. Ser. 1341 (3). https://doi.org/10.1088/1742-6596/ 1341/3/032005.
- Firdaus et al., 2021. Phenethyl p-coumarate and N-Phenethyl-p-coumaramide: synthesis, characterization. docking studies, and anticancer activity through P388 cell, Sains Malaysiana, 51(4) 1085–1097, http://dx.doi.org/10.1016/j. encep.2012.03.001.
- Firdaus, S.N., Hariani, F., Syadza, R., Herlina, A.N., Muzdalifah, W., 2020. Novel hydroxycinnamamide from morpholine and pyrrolidine: Synthesis, characterization, docking study, and anticancer activity against P388 leukemia murine cells. J. Appl Pharm. Sci. 11 (01), 40–48. https://doi.org/ 10.7324/japs.2021.110104.
- Firdaus, D.R., Husain, T., Naid, N.H., Soekamto, S.S., Islam, M.F., 2017. Synthesis of Piperidine and Morpholine Amides of Ferulic Acid and their Bioactivity against P-388 Leukemia Cells. Int. J. ChemTech Res. 10 (1), 27–33.
- Firdaus, N.H.S., Karim, A., 2009. Sintesis Senyawa p-Hidroksisinamamida dari Asam p-Hidroksisinamat Melalui Reaksi Esterifikasi dan Amonolisis. J. Chem. Acta 2 (2).
- Firdaus, A.F., Soekamto, N.H., 2020. Synthesis of a cinnamic acid derivative and bioactivity as an anticancer based on Result Quantitative Structure Activity Relationship (QSAR) analysis. Indones. Chim. Acta 13 (1), 23–29.
- Firdaus, Soekamto, N.H., Seniwati, Islam, M.F., Sultan, 2018. Phenethyl ester and amide of Ferulic Acids: Synthesis and bioactivity against P388 Leukemia Murine Cells. J. Phys. Conf. Ser. 979 (1), pp. https://doi.org/10.1088/1742-6596/979/1/ 012016.

- Firdaus, N.H., Soekamto, S.F., Tahar, M., 2021. A Caffeic Acid Derivative Potential for Anticancer. Indones. Chim. Acta 13 (2), 38–42. https://doi.org/10.20956/ica. v13i2.10962.
- Firdaus, N.H., Soekamto, S.F., Rasyid, H., 2021. N-Benzylhydroxycinnamamides: Synthesis, Docking Study and Cytotoxicity against Leukemia Murine P388 Cells. Iran. J. Chemsitry.
- Giles, M.E. et al., 2004. Development of a manufacturing process for sibenadet hydrochloride, the active ingredient of viozan. Org. Process Res. Dev. 8 (4), 628– 642. https://doi.org/10.1021/op049953y.
- Hanwell, M.D., Curtis, D.E., Lonie, D.C., Vandermeersch, T., Zurek, E., Hutchison, G.R., 2012. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4 (17), 1–17.
- Iman, M., Davood, A., Banarouei, N., 2014. QSAR study of chalcone derivatives as anti- Leishmania agents. Turkish J. Chem. 38, 716–724. https://doi.org/10.3906/ kim-1307-33.
- Jalali-Heravi, M., Kyani, A., 2004. Use of computer-assisted methods for the modeling of the retention time of a variety of volatile organic compounds: A PCA-MLR-ANN approach. J. Chem. Inf. Comput. Sci. 44 (4), 1328–1335. https:// doi.org/10.1021/ci0342270.
- Jawarkar, R.D. et al., 2022. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CLpro Inhibitor: GA-MLR QSAR modeling supported by molecular Docking, molecular dynamics simulation and MMGBSA calculation approaches. Arab. J. Chem. 15, (1). https://doi.org/10.1016/j. arabjc.2021.103499 103499.
- Kennard, R.W., Stone, L.A., Feb. 1969. Computer aided design of experiments. Technometrics 11 (1), 137–148. https://doi.org/10.1080/ 00401706.1969.10490666.
- Labjar, H., Labjar, N., Kissi, M., 2022. QSAR Anti-HIV Feature Selection and Prediction for Drug Discovery Using Genetic Algorithm and Machine Learning Algorithms BT - Computational Intelligence in Recent Communication Networks. In: Ouaissa, M., Boulouard, Z., Ouaissa, M., Guermah, B. (Eds.), Computational intelligence in Recent Communication Networks. Springer International Publishing, Cham, pp. 191–204.
- Narasimhan, B., Belsare, D., Pharande, D., Mourya, V., Dhake, A., 2004. Esters, amides and substituted derivatives of cinnamic acid: synthesis, antimicrobial activity and QSAR investigations. Eur. J. Med. Chem. 39, 827–834. https://doi.org/ 10.1016/j.ejmech.2004.06.013.
- Nekoeinia, M., Yousefinejad, S., 2021. QSAR analysis of the acetylcholinesterase inhibitory activity of some tertiary amine derivatives of cinnamic acid. Struct. Chem. 32 (3), 1123–1132. https://doi.org/10.1007/s11224-020-01683-w.
- O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., 2011. Open Babel: An open chemical toolbox. J. Cheminform. 3 (33), 1–14 https://jcheminf.biomedcentral.com/track/pdf/10.1186/1758-2946-3-33.
- Peperidou, A., Pontiki, E., Hadjipavlou-litina, D., 2017. Multifunctional cinnamic acid derivatives. Molecules 22 (1247), 1–17. https://doi.org/ 10.3390/molecules22081247.
- Schwöbel, J.A.H., Ebert, R.U., Kühne, R., Schüürmann, G., 2011. Prediction models for the Abraham hydrogen bond donor strength: Comparison of semi-empirical, ab initio, and DFT methods. J. Phys. Org. Chem. 24 (11), 1072–1080. https://doi. org/10.1002/poc.1834.
- Serra, A., Önlü, S., Festa, P., Fortino, V., Greco, D., 2020. MaNGA: a novel multi-niche multi-objective genetic algorithm for QSAR modelling. Bioinformatics 36 (1), 145–153. https://doi.org/10.1093/bioinformatics/btz521.
- Sova, M., 2012. Antioxidant and antimicrobial activities of cinnamic acid derivatives. Mini-Reviews Med. Chem. 12, 749–767.
- Teraishi, F. et al., Aug. 2005. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 579 (19), 4069–4075. https://doi.org/10.1016/j.febslet.2005.06.031.
- Thakur, A., Parashar, A., Sharma, V.K., Kumar, A., Mehta, V., 2022. 2D-QSAR and Molecular Docking based virtual screening of the herbal molecules against Alzheimer's Disorder: An approach to predict CNS activity, bioRxiv, p. 2022.10.08.511422, doi: 10.1101/2022.10.08.511422.
- Tropsha, A., Gramatica, P., Gombar, V.K., 2003. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 22 (1), 69–77. https://doi.org/10.1002/ qsar.200390007.
- Yalcin, S., 2020. Molecular Docking, Drug Likeness, and ADMET Analyses of Passiflora Compounds as P-Glycoprotein (P-gp) Inhibitor for the Treatment of Cancer. Curr. Pharmacol. Reports 6 (6), 429–440. https://doi.org/10.1007/ s40495-020-00241-6.
- Yap, C.W., 2011. PaDEL-Descriptor: an open source software to calculate molecular descriptors and fingerprints. J. Comput. Chem. 32, 1466–1474. https://doi.org/ 10.1002/jcc.